[go: up one dir, main page]

PL3416966T3 - Sposób wytwarzania kwasów [7-[[4-fenylo-5-alkoksykarbonylo-2-tiazol-2-ilo-1,4-dihydropirymidyn-6-ylo]metylo]-3-okso-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pirazyn-2-ylo]alkilokarboksylowych - Google Patents

Sposób wytwarzania kwasów [7-[[4-fenylo-5-alkoksykarbonylo-2-tiazol-2-ilo-1,4-dihydropirymidyn-6-ylo]metylo]-3-okso-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pirazyn-2-ylo]alkilokarboksylowych

Info

Publication number
PL3416966T3
PL3416966T3 PL17705612T PL17705612T PL3416966T3 PL 3416966 T3 PL3416966 T3 PL 3416966T3 PL 17705612 T PL17705612 T PL 17705612T PL 17705612 T PL17705612 T PL 17705612T PL 3416966 T3 PL3416966 T3 PL 3416966T3
Authority
PL
Poland
Prior art keywords
dihydropyrimidin
pyrazin
thiazol
imidazo
alkoxycarbonyl
Prior art date
Application number
PL17705612T
Other languages
English (en)
Inventor
Junli Chen
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3416966T3 publication Critical patent/PL3416966T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17705612T 2016-02-19 2017-02-16 Sposób wytwarzania kwasów [7-[[4-fenylo-5-alkoksykarbonylo-2-tiazol-2-ilo-1,4-dihydropirymidyn-6-ylo]metylo]-3-okso-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pirazyn-2-ylo]alkilokarboksylowych PL3416966T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016074132 2016-02-19
EP17705612.4A EP3416966B1 (en) 2016-02-19 2017-02-16 Process for the preparation of [7-[[4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]alkyl carboxylic acids
PCT/EP2017/053443 WO2017140750A1 (en) 2016-02-19 2017-02-16 Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

Publications (1)

Publication Number Publication Date
PL3416966T3 true PL3416966T3 (pl) 2022-01-17

Family

ID=58054130

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17705612T PL3416966T3 (pl) 2016-02-19 2017-02-16 Sposób wytwarzania kwasów [7-[[4-fenylo-5-alkoksykarbonylo-2-tiazol-2-ilo-1,4-dihydropirymidyn-6-ylo]metylo]-3-okso-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pirazyn-2-ylo]alkilokarboksylowych

Country Status (16)

Country Link
US (1) US10927116B2 (pl)
EP (2) EP3954691A1 (pl)
JP (1) JP6672471B2 (pl)
KR (2) KR102255228B1 (pl)
CN (1) CN108718527B (pl)
AR (1) AR107633A1 (pl)
AU (2) AU2017219189B2 (pl)
CA (1) CA3011650A1 (pl)
ES (1) ES2899369T3 (pl)
HR (1) HRP20211816T1 (pl)
IL (2) IL260153B (pl)
MX (1) MX380516B (pl)
PL (1) PL3416966T3 (pl)
SG (2) SG10202110927VA (pl)
SI (1) SI3416966T1 (pl)
WO (1) WO2017140750A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132276A1 (en) * 2014-03-07 2015-09-11 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JP7260488B2 (ja) 2017-06-26 2023-04-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ジヒドロピリミジン化合物、及び医薬におけるその使用
KR20200020887A (ko) 2017-06-27 2020-02-26 얀센 파마슈티카 엔.브이. 헤테로아릴디히드로피리미딘 유도체 및 b형 간염 감염의 치료 방법
AU2018351400B2 (en) * 2017-10-18 2022-12-15 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
TW202035412A (zh) * 2018-12-20 2020-10-01 比利時商健生藥品公司 雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
MA54560A (fr) * 2018-12-20 2021-10-27 Janssen Pharmaceutica Nv Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b
KR102732006B1 (ko) * 2019-03-25 2024-11-20 에프. 호프만-라 로슈 아게 Hbv 코어 단백질 알로스테릭 조절제 화합물의 고체 형태
BR112021024398A2 (pt) 2019-06-06 2022-01-18 Hoffmann La Roche Processo alternativo para a preparação de ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-di-hidropirimidin-6-il]metil]-3-oxo-5,6,8,8a-tetra-hidro-1h-imidazo[1,5-a]pirazin-2-il]-carboxílico
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
KR20220041120A (ko) * 2019-07-31 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 디히드로피리미딘 유도체 및 hbv 감염 또는 hbv-유도성 질환의 치료에 있어서의 이의 용도
CN112707910A (zh) * 2019-10-24 2021-04-27 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
MX2022013205A (es) * 2020-04-28 2022-11-14 Hoffmann La Roche Proceso para la preparacion de un acido piperazin-2-carboxilico quiral.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
CN100453542C (zh) 2007-04-30 2009-01-21 广东东阳光药业有限公司 2-杂环取代的二氢嘧啶消旋化合物的拆分方法
WO2010069147A1 (zh) 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
KR102148678B1 (ko) 2012-08-24 2020-08-27 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
AU2013311705A1 (en) 2012-09-10 2015-02-05 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
JP6533217B2 (ja) 2013-05-17 2019-06-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染症の治療および予防のための6−架橋ヘテロアリールジヒドロピリミジン類
WO2015132276A1 (en) * 2014-03-07 2015-09-11 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AR101319A1 (es) * 2014-07-31 2016-12-07 Hoffmann La Roche Resolución quiral de los ésteres del ácido 4-aril-2-tiazol-2-il-1,4-dihidropirimidin-5-carboxílico
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues

Also Published As

Publication number Publication date
IL260153B (en) 2021-10-31
MX380516B (es) 2025-03-12
AU2017219189B2 (en) 2021-04-01
IL260153A (en) 2018-07-31
WO2017140750A1 (en) 2017-08-24
CA3011650A1 (en) 2017-08-24
JP6672471B2 (ja) 2020-03-25
JP2019507144A (ja) 2019-03-14
US10927116B2 (en) 2021-02-23
EP3416966B1 (en) 2021-09-29
US20190010155A1 (en) 2019-01-10
BR112018016932A2 (pt) 2019-01-08
AU2017219189A1 (en) 2018-06-28
SG11201805595TA (en) 2018-07-30
CN108718527A (zh) 2018-10-30
ES2899369T3 (es) 2022-03-11
KR20180104177A (ko) 2018-09-19
HRP20211816T1 (hr) 2022-03-04
IL286912A (en) 2021-10-31
EP3954691A1 (en) 2022-02-16
KR102255228B1 (ko) 2021-05-25
AU2021203860A1 (en) 2021-07-08
EP3416966A1 (en) 2018-12-26
SI3416966T1 (sl) 2022-01-31
KR20210059801A (ko) 2021-05-25
CN108718527B (zh) 2022-06-28
AR107633A1 (es) 2018-05-16
MX2018009944A (es) 2018-11-09
SG10202110927VA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
PL3416966T3 (pl) Sposób wytwarzania kwasów [7-[[4-fenylo-5-alkoksykarbonylo-2-tiazol-2-ilo-1,4-dihydropirymidyn-6-ylo]metylo]-3-okso-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pirazyn-2-ylo]alkilokarboksylowych
IL266170A (en) A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
EP3166927A4 (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
ZA201804783B (en) Process for the preparation of 4-alkoxy-3-acetoxypicolinic acids
IL260465B (en) A process for preparing an antibody-rifamycin conjugate
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
IL276483A (en) A continuous process for the preparation of trazodone
ZA201804871B (en) Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds
EP3166928A4 (en) Process for the preparation of 3-hydroxypicolinic acids
EP3422855A4 (en) PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-HYDROXYPICOLIC ACIDS
EP3433242A4 (en) METHOD FOR PRODUCING HETEROARYL CARBONIC ACIDS
ZA201804877B (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
IL288585A (en) Alternative Process for the Preparation of 4-Phenyl-5-Alkoxycarbonyl-2-thiazol-2-yl-4,1-dihydropyrimidin-6-yl]methyl]-3-oxo-8,8,6,5a-tetrahydro-1h-imidazo[ 5,1-a]pyrazin-2-yl]-carboxylic acid
PT3277687T (pt) Derivados de 7-(morfolin-4-il)pirazole[1,5-a]pirimidina que são úteis para o tratamento de doenças imunitárias ou inflamatórias ou cancro
IL279410A (en) Process for preparing Quinmark
AU2018297073A1 (en) Process for the preparation of morphinane compounds
EP3676272A4 (en) IXAZOMIB CITRATE PREPARATION PROCESS
HK40061337B (en) Alternative process for the preparation of [[[4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
IL268103A (en) A process for the preparation of chiral pyrrolidine-2-yl-methanol derivatives
HK40027184B (en) Process for the preparation of pyrido[1,2-a]pyrimidin-4-one derivatives
HK1238236A1 (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors